NicErase-SL lobeline sulfate sublingual tablets data

DYGN announced that its 750-patient, Phase III trial failed to demonstrate a statistically significant difference between NicErase-SL tablets and placebo. Based on the results, DYGN will discontinue its NicErase-SL program. ...